Carlyle Credit Income Fund (NASDAQ: CCID) logs 10.44% GAAP yield on CLO portfolio
Carlyle Credit Income Fund (CCIF/CCID) reported its third-quarter 2026 results, showing net investment income of $0.07 per common share and a total weighted average GAAP yield of 10.44% on its CLO portfolio. The fund declared monthly common dividends of $0.06 per share for September, October, and November 2026, representing an annualized rate of 24.91%. CCIF's portfolio consists of 42 CLO holdings with exposure to 1,450 underlying obligors, and its net asset value per common share was $3.32 as of June 30, 2026.
Earnings call transcript: VolitionRX misses Q2 2026 estimates as shares slip
VolitionRX (VNRX) reported a wider-than-expected loss and lower revenue for Q2 2026, causing shares to slip. Despite the financial miss, the company highlighted progress in reducing operating costs, advancing scientific data, and developing partnerships in sepsis, cancer, and veterinary diagnostics. Management indicated that revenue remains unpredictable and declined to provide full-year 2026 guidance, focusing instead on long-term strategic milestones and licensing agreements.
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
LivaNova reported record Q2 2026 revenue of $390.6 million and adjusted diluted EPS of $1.26, exceeding prior-year figures, driven by strong demand in Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted diluted EPS guidance to $4.30-$4.40, citing improved market share, Essenz upgrade cycles, and favorable Medicare reimbursement. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for oxygenator components and provided updates on its innovation pipeline, including next-generation oxygenators and advancements in its Obstructive Sleep Apnea program.
QIAGEN N.V. (NYSE: QGEN) sets $0.35 dividend and $200M buyback cap
QIAGEN N.V. (NYSE: QGEN) announced it will convene its 2026 Annual General Meeting on June 24, 2026. Shareholders will vote on a proposed cash dividend of $0.35 per ordinary share, totaling approximately $72 million, payable July 14, 2026. Additionally, the agenda includes authorizing a synthetic share repurchase of up to $200 million via capital repayment, alongside other corporate governance and remuneration policy updates.
QT Imaging appoints two regional sales vice presidents By Investing.com
QT Imaging Holdings Inc. (NASDAQ:QTI) has appointed Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West, effective July 2026. These appointments mark a strategic shift from a distributor-led sales model to a direct sales approach for its Breast Acoustic CT Scanner, though it will continue working with NXC Imaging, Inc. The new team aims to strengthen customer engagement and support clinical adoption, with potential expansion of commercial resources in 2027 and a focus on developing quantitative imaging biomarkers and Software-as-a-Service offerings.
Citigroup readies US$2 bil debt deal for KKR’s Integer buyout — Bloomberg
Citigroup is leading a US$2.45 billion debt financing package for KKR & Co Inc.'s acquisition of medical-device maker Integer Holdings. The financing includes a US$2.1 billion term loan and a US$350 million revolving credit facility, with Barclays Plc, UBS Group AG, and Jefferies Financial Group Inc. also participating. This marks Citigroup's second lead role in a significant medical-device buyout this year, following an US$8.75 billion debt financing for Hologic Inc.
Contrast-Enhanced Mammography (CEM) Explained
This article explains Contrast-Enhanced Mammography (CEM), an imaging option that helps detect breast cancer, especially in women with dense breasts. Dr. Wei Wang, Associate Director of R&D Innovation at Hologic, discusses how CEM uses an iodine-based contrast agent to highlight abnormal blood vessel growth associated with tumors, offering an alternative to MRI. The technology provides crucial functional information for radiologists and is evolving to extract more meaningful data for improved patient decision-making.
Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Medical equipment maker Revvity has increased its annual profit and revenue forecasts after exceeding Wall Street expectations for the second quarter. This improvement is attributed to stronger demand for its drug-development tools and diagnostic testing products, with AI-related work contributing to incremental demand. Despite a decline in its life sciences unit, the company's diagnostics business saw significant growth.
KKR to take medical equipment maker Integer Holdings private in $5.7 billion deal
Private equity firm KKR is acquiring medical equipment manufacturer Integer Holdings in an all-cash deal valued at approximately $5.7 billion, including debt assumption. KKR will pay $127 per share, a 4.78% premium over Integer's Friday closing price. This acquisition deepens KKR's healthcare exposure and follows Integer's recent agreement with activist investor Irenic Capital Management.
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
A national Health Trends® study by Quest Diagnostics and Hologic, Inc. found that women testing positive for bacterial vaginosis (BV) were over three times more likely to also have non-viral sexually transmitted infections (STIs). The study, which analyzed data from 1.5 million women between 2022 and 2024, revealed that 12% of BV-positive women were co-infected with at least one STI, compared to 3.8% of BV-negative women. These findings emphasize the need for comprehensive diagnostic approaches and continued research into the link between vaginal microbiome changes and STI susceptibility.
Teleflex Number of Employees 2026 | Employee Count & Headcount Data
Teleflex, Inc. (TFX) had approximately 15,496 employees worldwide as of March 2026, marking a 3.2% growth from 2023. The company, headquartered in Wayne, Pennsylvania, is actively hiring with 295 job postings in 2026, though hiring velocity has declined. Its workforce is primarily concentrated in the United States, and the average employee salary is $75,478.
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
Ceribell, a medical technology company, announced the appointments of Thomas West and Sharon O’Keefe to its Board of Directors. West brings experience scaling medical technologies and led companies through significant acquisitions, while O’Keefe offers extensive leadership experience from major academic health systems. Their combined expertise is expected to be invaluable as Ceribell expands its point-of-care brain monitoring platform, currently deployed in over 680 U.S. hospitals.
Smith & Nephew Number of Employees 2026 | Employee Count & Headcount Data
As of March 2026, Smith & Nephew plc has approximately 18,547 employees worldwide, marking a 1.3% decline since 2023 but a recovery from a low in 2025 Q1. The company is actively hiring with 1,218 active job postings in 2026, a 44.1% increase from 2025. The workforce is concentrated in the United States, Costa Rica, and the United Kingdom, with India being the fastest-growing location, and the average global salary is $71,719.
Hologic Inc Lobbyists, 2022
This OpenSecrets.org page details the lobbyists working for Hologic Inc in 2022. It lists 19 lobbyists, 15 of whom have revolving door experience from federal government positions. The data breaks down lobbyists by hiring firm and provides a comprehensive roster for the year.
Hologic stock trades steadily as breast health and diagnostics revenue support valuation
Hologic's stock is maintaining a steady valuation, supported by consistent revenue from its breast health systems and molecular diagnostics segments. Despite the normalization of COVID-19 testing sales from their peak, the company reported significant revenue growth in fiscal 2022, primarily driven by diagnostics and surgical products, and maintained strong operating margins. The article highlights that recurring revenue from breast health and non-COVID molecular diagnostics is crucial for sustaining its profitability above pre-pandemic levels.
Hologic stock steadies as breast health and diagnostics revenue drive outlook
Hologic's stock reflects a mixed picture, balancing stable breast health and diagnostics revenue against cautious guidance. The company, focused on women's health, reported approximately $1.0 billion in quarterly revenue, driven by these core segments despite a normalization in COVID-related testing. Its strong cash flow, manageable debt, and capital allocation strategy, including share repurchases, support its position as a stable, moderately growing medical technology group.
From Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation
Joseph B. LaBruzzo, previously with leading medical device companies like Hologic, has joined Ark Surgical as President & CEO of U.S. Operations and Board Member. He is drawn to Ark Surgical's LapBox, an innovation addressing unmet needs in gynecologic surgery by enhancing safety during minimally invasive procedures. LaBruzzo believes this technology has the potential to become a standard of care, reflecting his commitment to improving patient outcomes in women's health.
3D Mammography Machines Market To Reach New Heights by 2035 Amid AI Adoption and Global Screening Programs - News and Statistics
The global 3D mammography machines market is expected to experience sustained growth, projected at an 8.5% compound annual growth rate from 2026 to 2035, driven by AI integration and expanding screening programs. Key market drivers include the superiority of Digital Breast Tomosynthesis (DBT) over 2D mammography, rising breast cancer incidence, and increased adoption in emerging markets. Despite challenges like high system costs and supply chain constraints, widespread replacement of older 2D systems and significant growth in Asia-Pacific are anticipated.
Hologic stock trades steadily as imaging and diagnostics revenue supports margins
Hologic stock maintains steady trading as its diagnostics and surgical portfolio, focused on women's health technology, demonstrates consistent revenue growth and stable margins. The company benefits from a diversified product mix, including high-margin diagnostic consumables and imaging systems, with international expansion further supporting its financial performance. Investors are watching segment trends and market positioning, backed by a strong operating income and strategic investments in R&D.
RadNet schedules Q2 2026 financial results conference call
RadNet, Inc. has announced its second quarter 2026 financial results conference call will take place on Monday, August 10, 2026, at 7:30 a.m. Pacific Time. Investors can access the live call via domestic and international dial-in numbers, and an archived replay will also be available. RadNet is a major provider of diagnostic imaging services and AI solutions, operating numerous outpatient imaging centers and developing AI tools under its DeepHealth brand.
Hologic stock trades steadily as diagnostics and surgical revenue support margins
Hologic's stock is performing steadily, supported by strong revenue growth and resilient margins in its diagnostics and surgical segments. The company's recent quarterly results show a shift from pandemic-driven testing sales to a more balanced portfolio, with core molecular diagnostics and cytology products underpinning recurring revenue. Despite some cost pressures, Hologic maintains profitability levels above pre-pandemic benchmarks, with continued investment in R&D and diversification through breast health and surgical offerings.
Hologic stock trades steadily as recent earnings highlight diagnostics growth
Hologic Inc. (HOLX) stock has been trading steadily, supported by strong fundamentals thanks to its diagnostics and surgical franchises. The company reported higher revenue and improved profitability in Q2 fiscal 2025, driven by its diagnostics segment and solid demand in breast and skeletal health. Hologic has also provided stable full-year guidance and maintains strong cash flow generation.
Hologic stock trades steadily as Q2 2025 earnings show higher margins
Hologic's Q2 2025 earnings reveal a solid financial profile driven by growing margins and consistent cash generation, particularly in women’s health diagnostics. The company's revenue stability across key segments like diagnostics, breast and skeletal health, and gynecologic surgical products, coupled with a robust balance sheet, positions it well for continued innovation and sustained profitability in the medical technology sector. This performance underpins Hologic's stability, making it an attractive prospect for investors interested in the sustainability of diagnostic volumes and effective capital allocation.
Hologic (HOLX) Q4 2024 earnings summary
Hologic (HOLX) reported strong Q4 2024 results, with revenue reaching $987.9 million, up 4.5% year-over-year, and non-GAAP EPS of $1.01. The company saw broad-based growth across Diagnostics, Breast Health, and Surgical segments, driven by strategic acquisitions and international expansion. Hologic also announced a $250 million accelerated share repurchase program and provided optimistic financial guidance for FY2025, projecting revenue between $4.15 billion and $4.20 billion.
Hologic stock trades steadily as breast health revenue supports outlook
Hologic stock is trading steadily on Nasdaq, supported by strong quarterly results for Q2 fiscal 2025 which showed increased revenue in both its Diagnostics and Breast Health segments. The company reported double-digit growth in Diagnostics and mid-single-digit growth in Breast Health, contributing to an improved operating margin. Hologic's capital allocation strategy includes continued investment in R&D and significant share repurchases, with a net leverage ratio indicating financial flexibility.
Hologic stock trades steadily as diagnostics growth offsets softer imaging demand
Hologic's stock performance is analyzed, showing stable diagnostics revenue balancing softer demand in its imaging and surgical segments. The company reported a 5% increase in net revenue for Q2 fiscal 2024, driven by its diagnostics business, and maintained robust adjusted operating margins and EPS. Hologic's focus on women's health and recurring diagnostics revenue provides a strong foundation, while its diversified segments offer cyclical growth opportunities.
Full Transcript: AngioDynamics Q4 2026 Earnings Call
AngioDynamics reported strong Q4 fiscal year 2026 results with an 8% revenue increase to $86.6 million, driven by 16.7% growth in its MedTech segment, which now accounts for 47% of total revenue. The company highlighted 20 consecutive quarters of double-digit growth for its Aureon platform and a 64.5% revenue increase for NanoKnife, particularly in prostate care. For fiscal 2027, AngioDynamics projects 5-6.5% total revenue growth and 12-15% MedTech sales growth, emphasizing continued investment in clinical data, R&D, and a debt-free balance sheet.
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening
Hologic, Inc. announced an expanded CE-IVDR marking for its Aptima® HPV Assay in the European Union and the UK, now approved for self-collected vaginal samples. This expansion aims to improve cervical cancer screening participation rates, especially for women facing barriers to traditional screening methods. While self-sampling increases access, positive results still necessitate clinician-collected cervical samples for appropriate follow-up care and management.
Hologic’s Aptima HPV Test Wins CE Mark for Self-Collected Samples
Hologic's Aptima HPV test has received expanded CE-IVDR marking in the EU and UK for self-collected vaginal samples, aiming to increase HPV screening rates, especially in under-screened populations. This approval allows for an alternative screening method in healthcare settings for cervical cancer detection. While self-sampling improves participation, clear follow-up steps are crucial for positive results.
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening
Hologic, Inc. announced that its Aptima® HPV Assay has received an expanded CE-IVDR marking in the European Union and the UK, now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This expansion aims to improve cervical cancer screening participation rates, especially among women who face barriers to traditional screening, by offering an alternative self-collection method in a healthcare setting. The company emphasizes the importance of follow-up care for positive results from self-collected samples to ensure appropriate clinical management.
Hologic stock reflects steady diagnostics demand in women’s health
Hologic is a leading global medical technology company specializing in women's health diagnostics and solutions. The company's business model relies on recurring demand from hospitals and laboratories for its imaging, surgical, and molecular testing products, which are crucial for breast cancer detection, cervical cancer screening, and other gynecologic procedures. Hologic focuses on an installed base model with consumables and service contracts, providing stable revenue streams and long-term growth opportunities in the evolving healthcare landscape.
Midwest Trust Co Acquires 58,175 Shares of Blackstone Inc. $BX
Midwest Trust Co significantly increased its holdings in Blackstone Inc. (NYSE:BX) by 30.8% in the first quarter, adding 58,175 shares to its portfolio, bringing its total to 246,976 shares valued at $28.4 million. Other institutional investors like Vanguard Group, Morgan Stanley, and State Street Corp also adjusted their positions in Blackstone. The article highlights recent analyst ratings, financial performance, dividend information, and insider trading activity for Blackstone.
Torray Investment Partners LLC Has $18.99 Million Stake in Blackstone Inc. $BX
Torray Investment Partners LLC increased its stake in Blackstone Inc. by 18.4% in the first quarter, bringing its total holdings to 165,160 shares valued at approximately $18.99 million. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $147.10 despite some recent target adjustments. Blackstone reported strong Q1 earnings, beating EPS estimates and showing a 10% year-over-year revenue increase, while also distributing a $1.16 quarterly dividend.
Vulcan Materials (VMC) Stock Loses Russell 1000 Index Spot
Vulcan Materials (NYSE:VMC) has been removed from the Russell 1000 Dynamic Index, an adjustment that could impact trading activity and index-linked ownership of the stock. While the removal does not affect the company's core operations in construction aggregates, it may influence liquidity and who holds the stock, especially around rebalance dates. Investors are advised to monitor trading volumes, institutional ownership, and compare Vulcan Materials' upcoming earnings reaction against peers, focusing on fundamentals versus index mechanics.
Private equity firms reportedly set $4B price on Hologic Surgical unit
Private equity firms Blackstone and TPG, who took Hologic private in April, are now reportedly looking to sell the Hologic Surgical unit for over $4 billion. This move aims to help the firms pay down debt and repay investors amidst "strains in private credit." Meanwhile, former Baxter head José E. Almeida has taken over as CEO of the now-private Hologic.
Blackstone (BX) and TPG Target Over $4B from Hologic's Surgical Unit Sale
Blackstone and TPG are aiming to raise over $4 billion by selling Hologic's surgical division to reduce debt from a previous leveraged buyout. This strategic move by the world's largest alternative-asset manager, Blackstone, reflects efforts to optimize its capital structure. The company's GF Score™ of 67 indicates relatively strong growth and profitability, though financial strength and recent insider selling suggest caution for investors.
Blackstone and TPG seek over $4B for Hologic unit - report (BX:NYSE)
Private equity firms Blackstone and TPG are reportedly looking to sell Hologic's surgical unit for over $4 billion. The sale's purpose is to help pay down debt and return cash from a significant leveraged buyout that occurred last year. This move by Blackstone and TPG indicates an effort to manage liabilities and generate returns from their investment.
Hologic highlights diagnostics portfolio as investors watch US healthcare demand
Hologic, a US-based medical technology company, is expanding its diagnostics and women's health portfolio, attracting investor attention due to trends in healthcare spending and innovation. The company's strong presence in diagnostic testing and breast/skeletal health, along with its molecular diagnostics platform, positions it to capture long-term demand driven by aging populations and preventive care. Investors are closely monitoring revenue trends, margin development, R&D spending, and exposure to hospital and outpatient volumes within Hologic's market context.
Blackstone, TPG seek over $4 billion for Hologic’s surgical unit, FT says
Private equity firms Blackstone and TPG are reportedly seeking over $4 billion for Hologic's surgical unit, which makes gynecological surgical equipment. This potential sale aims to help the firms pay down debt and reimburse investors following their $18.3 billion acquisition of Hologic last year. The move comes amid increasing redemption pressures in private credit funds, including Blackstone.
Blackstone, TPG seek over $4 billion for Hologic’s surgical unit, FT says
Private equity firms Blackstone and TPG are reportedly seeking over $4 billion for Hologic's surgical unit, according to the Financial Times. This potential sale follows their $18.3 billion acquisition of Hologic last year, and the firms are now looking to reduce debt and repay investors amidst strains in private credit markets. The division specializes in surgical equipment for gynecologists.
Blackstone, TPG seek over $4 billion for Hologic's surgical unit
Private equity firms Blackstone and TPG are reportedly seeking over $4 billion for medical technology firm Hologic's surgical unit, which specializes in surgical equipment for gynecologists. This potential sale follows their acquisition of Hologic for $18.3 billion last year, as they aim to pay down debt and return capital to investors amidst private credit market strains. Blackstone recently capped withdrawals from its flagship private credit fund due to increased redemption requests.
Blackstone, TPG seek over $4 billion for Hologic's surgical unit, FT says
Private equity firms Blackstone and TPG are reportedly looking to sell Hologic's surgical unit for more than $4 billion. This news comes via the Financial Times.
Hologic Inc focuses on diagnostics and women’s health as investors watch long-term growth
Hologic Inc. is a medical technology company specializing in diagnostics and women's health, offering imaging, molecular testing, and surgical solutions. The company's business model relies on both capital equipment sales and recurring revenue from consumables, appealing to investors looking for stable cash flows and long-term growth. Hologic's focus on areas like breast health, gynecologic health, and infectious disease testing, supported by continuous R&D and acquisitions, positions it as a significant player in the healthcare sector.
Hologic highlights diagnostics and imaging focus as demand for women's health solutions grows
Hologic, a medical technology company listed in the United States, focuses on diagnostics and medical imaging predominantly in women's health. The company's business model revolves around diagnostic platforms, imaging systems, and related consumables used for early disease detection. Hologic's strong presence in breast health and its ecosystem approach, combining hardware, software, and consumables, are key elements of its strategy in the competitive medtech market.
Hologic and Vossius take action against Siemens Healthineers over mammography system
The UPC's Düsseldorf local division has issued a sales ban against Siemens Healthineers' MAMMOMAT B.brilliant mammography system in Germany, France, and the Netherlands, following a patent infringement lawsuit filed by Hologic. The dispute centers on Hologic's EP 2 352 431 patent, which covers technology designed to prevent image blurring during mammography. Siemens Healthineers has announced an appeal against the ruling, which also dismissed its counterclaim for revocation and prior use rights.
Hologic stock leans on diagnostics and imaging
Hologic, a Nasdaq-listed medical technology company, primarily focuses on women's health, diagnostics, and breast-health systems. The company's business model relies on recurring testing and installed-base equipment, with its diagnostics franchise and breast-health products being key drivers. Hologic's stock performance is linked to procedure volume and consumables demand, operating within the U.S. healthcare and med-tech peer set.
Hologic removes BioZorb 3D bioabsorbable markers due to safety reasons
Hologic, Inc. is recalling its BioZorb Marker due to a significant number of reported complications and adverse events, including pain, infection, and device migration, though no deaths have occurred. The implantable radiographic marker, used to identify soft tissues like breast tissue for medical procedures, consists of both permanent titanium and resorbable plastic components. The recall comes after 252 reported injuries were linked to the device.
FDA updates Hologic BioZorb recall, citing 252 injuries
The FDA reported 252 injuries linked to Hologic’s BioZorb radiographic markers, almost two years after Hologic instructed customers to stop using the devices due to adverse events. While the company no longer manufactures these markers, healthcare providers are advised to monitor patients with implants for issues such as pain, infection, or device migration, though removal is not recommended. This update follows a warning letter the FDA issued to Hologic in December 2025 for failing to meet design requirements for the markers.
Ascendis drug data show leg alignment kept improving through 2 years
Ascendis Pharma reported positive Week 104 data from its pivotal ApproaCH trial for TransCon CNP in children with achondroplasia. The data showed continued improvements in lower extremity alignment, specifically tibial-femoral angle (TFA) and TFA Z-scores, over two years, with greater improvements in children with pre-existing genu varum. The treatment was generally well-tolerated, reinforcing its potential as a pharmacological treatment for achondroplasia.
Research Supports Hologic’s AI-Powered Mammography Tech for Detecting Challenging Cancers
New research validates Hologic's AI-driven mammography technology, Genius AI Detection, for effectively identifying invasive lobular cancers, which are often challenging to detect. A study by Massachusetts General Hospital found the AI solution correctly localized nearly 90% of confirmed invasive lobular cancers, including 43% initially missed by standard screenings. This indicates the strong potential for AI to support radiologists in detecting diverse breast cancer subtypes, improving early diagnosis for these difficult-to-spot cancers.
